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Most patients with hematologic malignancies have received extensive chemotherapy before hematopoietic
cell transplantation (HCT), resulting in neutropenia, lymphocytopenia, and use of antibiotics. Accordingly,
patients have a wide range of neutrophil counts, lymphocyte counts, and previous antibiotic use. The minimal
toxicity of the current conditioning regimen allowed us to ask whether peritransplantation neutrophil or
lymphocyte levels inﬂuences the risks of acute graft-versus-host disease (GVHD) or relapse. We analyzed
outcomes in 459 patients age 7-75 years (median, 57 years) who received conditioning with ﬂudarabine and
low-dose total body irradiation for HLA-matched HCT. We report 2 key ﬁndings. First, low neutrophil nadirs
within the ﬁrst 3 weeks post-HCT had signiﬁcant associations with increased risks of acute GVHD and 5-year
nonrelapse mortality, but showed no association with the risk of relapse. Second, high lymphocyte counts
immediately before HCT had signiﬁcant associations with reduced risks of relapse and overall mortality, but
no association with the risks of GVHD or nonrelapse mortality. These ﬁndings suggest that the immunologic
mechanisms involved in acute GVHD might differ from those that initiate graft-versus-tumor effects.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION and have characteristic microbiomes consisting of symbiotic,
Graft-versus-host reactions occur after allogeneic hema-
topoietic cell transplantation (HCT) despite advances in both
donorerecipient HLA matching and immunosuppressive
therapy. Graft-versus-host reactions can affect the recipient
hematopoietic system, which may translate into graft-
versus-tumor (GVT) effects in patients with hematologic
malignancies. These reactions can also affect the skin, gut,
and liver, and the resulting graft-versus-host disease (GVHD)
can increase the risk of mortality. In patients treated with
conventional HCT, acute GVHD is initiated by the effects of
high-intensity conditioning regimens, which cause tissue
damage and subsequent production of inﬂammatory cyto-
kines, translocation of bacterial products into the circulation,
and heightened donor T cell recognition of host antigens [1].
In a second phase, donor T cells are stimulated by minor
histocompatibility antigens presented directly by host
antigen-presenting cells [2,3] and indirectly by donor cells. In
the third step, activated effector T cells cause tissue injury
that is recognized clinically as GVHD.
We have developed a mild HCTconditioning regimen that
minimizes tissue damage and can be tolerated by patients
who are older or have serious comorbidities [4-7]. This
regimen makes it feasible to assess GVHD and GVT effects
apart from the effects of the conditioning. In these patients,
GVHD involvement of the liver has become very infrequent,
especially after the introduction of prophylactic ursodiol
[8,9]. Consequently, acute GVHD is now largely conﬁned to
skin and gut, both of which interface with the environmentedgments on page 797.
equests: Rainer Storb, MD, Fred Hutch-
Fairview Avenue N, D1-100, Seattle, WA
g (R. Storb).
2013 American Society for Blood and Marrow
13.02.006commensal bacteria [10,11]. The likely disturbance of
microbiomes by neutropenia and antibiotics in patients
undergoing chemotherapy before HCT, along with the sus-
pected roles of altered microbiomes in the development of
autoimmune diseases [10,11], raise the possibility that
changes in commensal ﬂora may modulate GVHD. In fact,
a study in mice showed that pretransplantation treatment
with the antibiotic ampicillin resulted in a loss of lactobacilli
and aggravation of GVHD, whereas reintroduction of lacto-
bacilli protected against GVHD [12]. Simultaneous studies in
human patients identiﬁed increased microbial disturbances
early after allogeneic HCT as a potential risk factor for
GVHD [12].
Most patients with hematologic malignancies have
received extensive chemotherapy, resulting in pancytopenia
and the use of broad-spectrum antibiotics. Accordingly, on
arriving at our transplant center, patients have a wide range
of neutrophil counts, lymphocyte counts, and previous
antibiotic use. The widely ranging blood counts and the
minimal toxicity of the conditioning regimen allowed us to
ask whether peritransplantation neutrophil or lymphocyte
levels inﬂuence the risks of acute GVHD or relapse (GVT
effect) after HLA-matched HCT from a related or unrelated
donor.METHODS
Patients
Between September 1, 2002, and December 31, 2010, 459 consecutive
patients with a hematologic malignancy were entered on prospective,
minimal-intensity conditioning trials at the Fred Hutchinson Cancer
Research Center that were registered with ClinicalTrials.gov. All patients
signed consent forms that were approved by the Fred Hutchinson Cancer
Research Center Institutional Review Board. Median patient follow-up was 5
years (range, 1.5 to 9.9 years).
Table 1 presents patient and disease characteristics. The median patient
age was 57 years (range, 7 to 75 years). Unmodiﬁed grafts consisted ofTransplantation.
Table 1
Patient and Disease Characteristics (n ¼ 459)*
Characteristic Value
Sex, n (%)
Female 183 (40)
Male 276 (60)
Patient age group, yr, n (%)
0-19 7 (2)
20-29 17 (4)
30-39 28 (6)
40-49 68 (15)
50-59 152 (33)
60-69 169 (37)
70-79 18 (4)
Patient age, yr, median (range) 57 (7-75)
Diagnosis, n (%)
Acute lymphoblastic leukemia 27 (6)
Acute myelogenous leukemia 111 (24)
Chronic lymphocytic leukemia 50 (11)
Chronic myelogenous leukemia 2 (<1)
Hodgkin lymphoma 29 (6)
Myelodysplastic syndrome 53 (12)
Myeloproliferative disorder 5 (1)
Multiple myeloma 86 (19)
Non-Hodgkin lymphoma 91 (20)
Waldenstrom disease 5 (1)
Relapse risk group [14], n (%)
Low 111 (24)
Standard 220 (48)
High 128 (28)
Conditioning regimen, n (%)
2 Gy total body irradiation 87 (19)
2 Gy total body irradiation þ ﬂudarabine 343 (75)
3 Gy total body irradiation þ ﬂudarabine 24 (5)
4 Gy total body irradiation þ ﬂudarabine 5 (1)
Previous high-intensity HCT, n (%)
No 243 (53)
Yesy 216 (47)
Donor, n (%)
HLA-identical sibling 217 (47)
Other HLA-matched related 4 (1)
HLA-matched unrelated 216 (47)
HLA-mismatched unrelatedz 22 (5)
HCT Comorbidity Index score, n (%)
0 83 (18)
1 45 (10)
2 96 (21)
3 113 (25)
4 45 (10)
5 38 (8)
6 25 (5)
7þ 12 (3)
Cytomegalovirus-seropositive status, n (%)
Patient 250 (54)
Donor 184 (40)
* All patients reported here were entered on prospective clinical trials
registered with ClinicalTrials.gov. Data on other patients (eg, those whose
insurance denied participation in clinical trials and thus were placed on
treatment plans) are not included in this analysis.
y Autologous HCT as part of tandem autologous/allogeneic HCT, n ¼ 114;
failed autologous HCT, n ¼ 87; preceding autologous HCT for other disease,
n ¼ 9; failed allogeneic HCT, n ¼ 15.
z Single HLA allele-mismatched.
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that contained a median of 8.6 (range, 0.2 to 29.9)  106 CD34þ cells/kg and
3.0 (range, 0.1 to 10.8)  108 CD3þ cells/kg. The patients had received
a median of 3 (range, 0 to 23) chemotherapy regimens before HCT. HCT
Comorbidity Index scores were assigned as described previously [13]; 51% of
the patients had serious comorbidities (score 3). Classiﬁcation as low,
standard, or high risk of relapse or progression for each disease and disease
stage was done following a previously described algorithm [14].
Conditioning and Postgrafting Immunosuppression
A total of 430 patients received 2 Gy of total body irradiation with
ﬂudarabine (n ¼ 343) or without ﬂudarabine (n ¼ 87) 30 mg/m2/day ondays -4, -3, and -2 before HCT (Table 1). Twenty-four patients received 3 Gy,
and 5 patients received 4 Gy of total body irradiation. Immunosuppression
after HCT included mycophenolate mofetil (28 days for related recipients [4]
and at least 96 days for unrelated recipients [5,6]) and a calcineurin inhib-
itor, either cyclosporine (n¼ 270) or tacrolimus (n¼ 189), for up to 180 days.
Thirty-seven unrelated donor graft recipients also received sirolimus as part
of a randomized trial [15]. All patients received prophylactic ursodiol from
approximately 14 days before transplantation until at least day 180 after
transplantation. Infection prophylaxis and treatment followed FHCRC
standard practice guideline including acyclovir for herpes simplex virus and
varicella zoster virus prophylaxis, ﬂuconazole for yeast prophylaxis,
trimethoprim-sulfamethoxazole for Pneumocystis jirovecii prophylaxis, and
monitoring for cytomegalovirus reactivation. Antibacterial prophylaxis with
levoﬂoxacin was started when the neutrophil count declined to <500 cells/
mL and was continued until the neutrophil count recovered to >500 cells/mL
for 2 consecutive days in the absence of infection. HCT was planned as an
outpatient procedure.
Post-HCT Monitoring
As a rule, patients underwent bone marrow aspiration to assess disease
status on days þ28, þ84, þ180, and þ365 post-HCT and as indicated
thereafter. Donor chimerism was evaluated on days þ28, þ84, and þ365.
Acute and chronic GVHD were graded as described previously [16-20]. The
diagnoses of relapse (deﬁned as recurrence of malignancy) and progression
were based on previously published criteria [14].
Causes of Death
Relapse mortality included death after relapse or progression of pre-
transplantation disease, regardless of other events. Nonrelapse mortality
(NRM) included all deaths without relapse or progression. GVHD mortality
included all deaths in patients with a history of GVHD who died while
receiving immunosuppressive therapy. Infection was listed as a cause of
death in patients without relapse, progression, or a history of GVHD.
Statistical Analysis
Overall survival (OS) was estimated by the Kaplan-Meier method [21].
Cumulative incidence rates of acute and chronic GVHD, NRM, and relapse
mortality were estimated as described previously [22]. Death was
a competing risk for all other endpoints. Relapse was a competing risk for
NRM, and NRM was a competing risk for relapse and relapse-related
mortality. Given that some time-to-event endpoints also occurred during
this time period, progressive neutrophil nadir was treated as a time-
dependent covariate when analyzed as a risk factor. Cox regression was
used in risk factor analysis for all time-to-event endpoints. Logistic regres-
sionwas used to analyze risk factors for neutropenia nadir<500 cells/mL. For
this analysis, pretransplantation neutropenia was deﬁned as the lowest
value from day-15 to day-1 before the start of the conditioning regimen.
For the purpose of display and characterization, neutrophil nadirs between
days þ1 to þ20 post-HCT were divided into 4 ranges.
All statistical analyses were adjusted to account for possible uneven
distribution of the following variables: related/unrelated donor, HLA allele-
level mismatch, recipient age (<50 years, 50 years); donorerecipient sex
match (F/M, other), ﬂudarabine use (no, yes), calcineurin inhibitor (CSP,
tacrolimus), diagnosis (multiple myeloma, lymphoma, other), and preceding
high-intensity transplant (yes, no). Statistical analyses involving neutrophil
nadir as a risk factor for acute and chronic GVHD, relapse, NRM, and overall
mortality were also adjusted for pretransplantation lymphocyte counts.
In separate analyses, pretransplantation lymphocyte counts were analyzed
as a risk factor for the same outcomes, with adjustments both for post-
transplantation neutrophil counts and for the other variables. Pre-
transplantation lymphocyte levels were determined based on the minimum
value between day-15 and day-1 before the start of the conditioning
regimen.
RESULTS
Post-HCT Neutrophil Nadir
Neutrophil counts declined exponentially after HCT,
reaching nadirs between days þ10 and þ15, followed by
exponential recoveries to the normal range by day þ30. This
is shown in Figure 1A, where the neutrophil nadirs are
divided into 4 ranges for purposes of illustration.
The strongest predictor for a neutrophil nadir of <500/mL
after HCT was a low neutrophil count before HCT (Table 2).
Compared with patients with pretransplantation neutrophil
counts >2,000/mL, those with counts between 500-1999/mL
Figure 1. Pretransplantation and posttransplantation neutrophil changes in
patients in 4 posttransplantation neutrophil nadir ranges (A), and pre-
transplantation and posttransplantation lymphocyte changes in patients in 4
pretransplantation lymphocyte count ranges (B).
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2.0-6.2; P < .0001), and those with counts <500/mL had an
OR of 5.94 (95% CI, 2.1-17; P ¼ .0009). Another risk factor for
low neutrophil nadirs after HCT was receiving a transplant
from an unrelated donor (OR, 3.62; 95% CI,1.9-6.8; P< .0001).
Patients withmutiple myeloma (OR, 0.24; 95% CI, 0.1-0.6; P¼
.002) and those who underwent previous high-intensity HCT
(OR, 0.46; 95% CI, 0.2-0.9; P ¼ .03) were signiﬁcantly less
likely to have a post-HCT nadir of <500 neutrophils/mL. No
signiﬁcant associations with neutrophil nadir were seenwith
donor age, patient age, CD34 cell dose, number of preceding
chemotherapy regimens, and HCT Comorbidity Index scores.
To estimate the effect size associated with these risk factors,
we analyzed the posttransplantation neutrophil nadir as
a continuous outcome on a log scale, with the results
expressed as nadir multipliers (Table 2); for example, a pre-
transplantation neutrophil count <500/mL reduced the
posttransplantation neutrophil nadir by 82%, and a diagnosis
of multiple myeloma increased the nadir by 54%.GVHD
Two hundred sixty-four patients developed grade II-IV
acute GVHD, including 101 with isolated gut GVHD, 60
with isolated skin GVHD, 102 with both skin and gut GVHD,
and 1 with isolated, stage 1 liver GVHD. Eight patients had
liver GVHD in addition to gut involvement. Among the 203
patients with gut GVHD, 159 (78%) had upper gut involve-
ment. The distribution of organ involvement in patients was
comparable over the range of neutrophil nadirs. The overallcumulative incidence rates of grade II-IV and grade III-IV
acute GVHD were 56% and 8%, respectively.
Table 3 presents posttransplantation neutrophil nadirs
per log decrease in neutrophil counts as risk factors for
GVHD. Signiﬁcantly increased hazard ratios (HRs) can be
seen for the association of neutrophil nadirs with grade II-IV
and grade III-IV acute GVHD and de novo chronic GVHD.
Cumulative incidence estimates of grade II-IV and grade
III-IV acute GVHD were analyzed within 4 subgroups of
patients based on neutrophil nadir. The results, presented in
Table 4, suggest that the neutrophil nadir represents
a continuous predictor of the risk of acute GVHD. For
example, the overall risk of grade II-IV acute GVHD rose from
36% in the highest nadir group to 69% in the lowest nadir
group, and the risk of grade III-IV acute GVHD tripled, from
3.5% to 11%.
Relapse or Progression, NRM, and OS at 5 Years
Table 3 also presents data on neutrophil nadir as a time-
dependent risk factor for relapse or progression, NRM, and
overall mortality. No statistically signiﬁcant association
between neutrophil nadir and relapse or progression is seen
(HR 1.11; P ¼ .39), whereas associations with increased NRM
and overall mortality were statistically signiﬁcant (HRs, 1.54
and 1.46, respectively; P ¼ .001 and <.0001, respectively).
Table 4 shows comparable 5-year relapse mortality in the
4 nadir groups, ranging from 32% to 39% (see also Figure 2A).
In contrast, 5-year NRM increased steadily from 3% in the
highest nadir group to 25% in the lowest nadir group (see
also Figure 2B). Five-year OS, affected both by relapse
mortality and NRM, ranged from 58% in the highest nadir
group to 40% in the lowest nadir group.
Causes of NRM
Eighty-seven patients died of nonrelapse causes. Of these,
78 (90%) died from complications related to GVHD and its
treatment, including 59 from bacterial, fungal, or viral
infections and 19 from organ failure, including bronchiolitis
obliterans organizing pneumonia. Among the 9 patients
without GVHD, 2 experienced late graft failure and died of
infection after receiving pentostatin and donor lymphocyte
infusion (on day þ158 and day þ344). Four patients died of
solid tumors (in 2 cases recurrent) at 2.9, 5.0, 5.1, and
5.5 years after HCT, and 2 died in car accidents at 1.3 and
2.5 years after HCT. One patient with a history of CNS
radiation, intrathecal chemotherapy, and 2 previous high-
intensity conditioning HCTs died on day þ97 from
leukoencephalopathy.
Pretransplantation Lymphocyte Counts
In the foregoing multivariate analyses, we used lympho-
cyte counts immediately before transplantation as a contin-
uous adjustment factor. We also analyzed pretransplantation
lymphocyte count as a continuous variable and trans-
plantation outcomes (Table 3), with posttransplantation
neutrophil nadir as an additional adjustment factor.
Although we found no statistically signiﬁcant associations
with acute GVHD, chronic GVHD, or NRM, we did ﬁnd that
a low lymphocyte count was predictive of signiﬁcantly
higher relapse risk (HR, 1.48; P ¼ .003) and increased overall
mortality (HR, 1.41; P ¼ .007).
DISCUSSION
The study has yielded two major new results: ﬁrst, that
the depth of the neutrophil nadir within the ﬁrst 3 weeks
Table 2
Multivariate Analysis of Risk Factors for Neutrophil Nadir <500/mL
Factor OR (95% CI) P Value Nadir Multiplier* P Value
Pre-HCT neutrophil level, mL
2000 1.0
500-1999 3.55 (2.0-6.2) <.0001 0.56 (0.42-0.75) <.0001
<500 5.94 (2.1-17) .0009 0.18 (0.12-0.27) <.0001
Disease group
ALL, AML, MDS, CML 1.0
HL, NHL, CLL 0.57 (0.3-1.1) .11 0.91 (0.66-1.27) .58
Multiple myeloma 0.24 (0.1-0.6) .002 1.54 (0.96-2.47) .08
Donor
Related 1.0
Unrelated 3.62 (1.9-6.8) <.0001 0.56 (0.39-0.80) .001
Patient age, years
<50 1.0
50-64 1.51 (0.8-2.8) .18 0.74 (0.53-1.05) .09
65 2.40 (0.8-7.2) .12 0.72 (0.45-1.16) .18
Donor age, years
<50 1.0
50 0.87 (0.5-1.7) .68 0.87 (0.59-1.27) .47
CD34 cell dose,  106/kg
5.9 1.0
<5.9 (lowest quartile) 1.29 (0.7-2.4) .41 0.91 (0.67-1.23) .55
Previous high-intensity HCT
No 1.0
Yesy 0.46 (0.2-0.9) .03 1.68 (1.18-2.39) .004
Previous chemotherapy regimens
0-3 1.0
4 0.95 (0.5-1.7) .87 0.92 (0.69-1.23) .59
HCT Comorbidity Index score
0-2 1.0
3 1.12 (0.7-1.9) .66 0.89 (0.68-1.15) .37
ALL indicates acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin’s lymphoma; MDS,
myelodysplastic syndrome; MPD, myeloproliferative disorder; NHL, non-Hodgkin lymphoma.
* Nadir is a continuous outcome on a log scale. The effects of risk factors are expressed as multipliers; for example, a pretransplantation count <500 reduces
the nadir by 82%, and a diagnosis of MM increases the nadir by 54%.
y Autologous HCT as part of tandem autologous/allogeneic HCT, n ¼ 114; failed autologous HCT, n ¼ 87; preceding autologous HCT for other disease, n ¼ 9;
failed allogeneic HCT, n ¼ 15.
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and associated NRM, but not with GVT effects, and second,
that peripheral blood lymphocyte counts immediately before
HCT were associated with GVT effects, but not with acute
GVHD or NRM. These ﬁndings suggest that the immunologic
mechanisms involved in acute GVHD differ from those that
initiate GVT effects.
The ﬁrst result shows that patients with the lowest
neutrophil nadirs had signiﬁcantly increased risks of both
acute GVHD and 5-year NRM compared with patients with
higher nadirs. For example, the risk of grade III-IV acute
GVHD rose steadily from 3.5% in the highest neutrophil nadir
range group to 11% in the lowest nadir group, and the cor-
responding risk of 5-year NRM rose from 3% to 25%. Our data
suggest that the neutrophil nadir might serve as a contin-
uous predictor of the risk for GVHD and NRM. Whereas the
risks of acute GVHD and NRM increased signiﬁcantly with
decreasing neutrophil nadir, both the cumulative incidence
rates and the HRs of relapse remained unchanged across the
range of neutrophil nadirs. It could be argued that some
diseases that are especially susceptible to GVTeffects, such as
B cell malignancies, were unevenly distributed among the
neutrophil nadir ranges, but our multivariate analyses were
adjusted for type of malignancy.
Not surprisingly, the most signiﬁcant factor predicting
low posttransplantation neutrophil nadir was pre-
transplantation neutropenia. Other factors included under-
lying malignancies, receipt of previous transplantation with
high-intensity conditioning, and receipt of an unrelated
donor graft, but these were adjusted for in all analyses. Lowpretransplantation neutrophil counts likely resulted from
extended chemotherapy and impaired marrow function
before referral for HCT. Typically, patients with neutropenia
are treated with prophylactic broad-spectrum antibiotics.
Antibiotics can impart unintended collateral damage to
symbiotic microorganisms that live in the human gastroin-
testinal tract [23]. Speciﬁcally, repeated exposure to broad-
spectrum antibiotics can dramatically alter the composition
of human gut microbial communities, and these changes can
persist for extended periods [24,25]. It is possible both the
neutropenia and the altered microbiota emerging after
antibiotic treatment can lead to a proinﬂammatory state that
induces production of cytokines, such as IFN-g, TNF-a, IL-1,
and IL-6, and increased expression of HLA-DR and cos-
timulatory molecules, not only on antigen-presenting cells,
but also on skin and gut epithelia. In this hypothetical
sequence of events, skin and gut epithelia might conceivably
present minor histocompatibility antigens to donor T cells,
thereby amplifying GVHD manifestations speciﬁcally in
these 2 organs at the exclusion of GVT effects or immune
reactions against other organs, such as those typically
involved in autoimmune diseases. Alternatively, indirect
antigen presentation from these cells might be enhanced by
low-grade inﬂammation associated with neutropenia and
altered microbial ﬂora.
Results from previous studies support the hypothesis that
gut and skin microbiomes can inﬂuence the development of
GVHD. Compared with conventially raised mice, “germ-free”
murine recipients of H2-incompatible HCT had less clinically
detectable GVHD, less pronounced histological GVHD
Table 3
Posttransplantation Neutrophil Nadir (per log Decrease in Absolute
Neutrophil Count as a Continuous Variable) and Pretransplantation Absolute
Lymphocyte Count (per Log Decrease in Absolute Lymphocyte Count as
a Continuous Variable) as Risk Factors for Various Outcomes*
Outcome No. of Events HR (95% CI) P Value
Posttransplantation neutrophil nadir
GVHD
Acutey
Grade II-IV 263 1.45 (1.2-1.7) <.0001
Grade III-IV 39 1.63 (1.1-2.4) .02
Chronic
Any 270 1.08 (0.9-1.3) .42
De novo 103 1.81 (1.2-2.8) .007
Relapse or progression 207 1.11 (0.9-1.4) .39
NRM 87 1.54 (1.2-2.0) .001
Overall mortality 241 1.46 (1.21-1.8) <.0001
Pretransplantation absolute lymphocyte count
GVHD
Acutey
Grade II-IV 263 1.17 (0.9-1.5) .23
Grade III-IV 39 0.94 (0.5-1.7) .84
Chronic
Any 270 0.94 (0.7-1.2) .62
De novo 103 0.82 (0.5-1.3) .40
Relapse or progression 207 1.48 (1.1-1.9) .003
NRM 87 1.00 (0.6-1.6) .99
Overall mortality 241 1.41 (1.1-1.8) .007
* Adjusted for donor (related, unrelated), HLA allele-level mismatch (no,
yes), patient age in years (<50, 50), donor/patient sex (F/M, other), HCT
Comorbidity Index score (0-2, 3), ﬂudarabine use (no, yes), GVHD
prophylaxis (cyclosporine, tacrolimus), diagnosis (multiple myeloma,
lymphoma, other), posttransplantation neutrophil nadir (continuous), and
previous high-intensity HCT (no, yes). The analysis of posttransplantation
neutrophil nadir was also adjusted for pretransplantation lymphocyte
counts (continuous). The analysis of pretransplantation lymphocyte levels
was also adjusted for posttransplantation neutrophil nadir (continuous).
y GVHD grade was not available for 1 patient; this case was excluded from
multivariate analysis.
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with aplastic anemia who received marrow grafts from
HLA-identical siblings experienced both signiﬁcantly less
acute GVHD and better survival when the transplantation
was performed in a protective, “bacteria-free” environment
compared with a conventional environment [29]. Similarly,
a pediatric study showed improved prevention of GVHDwith
suppression of microbial ﬂora [30]. In another study, human
HCT recipients randomly assigned to antibiotic prophylaxis
with ciproﬂoxacin and metronidazole had less acute GVHD
than those given ciproﬂoxacin alone [31]; the authors sug-
gested that anaerobic ﬂora, favored by ciproﬂoxacin mono-
therapy, played a role in the pathogenesis of acute GVHD.
In mice, outgrowth of Escherichia (E.) coli bacteria was
observed during gut GVHD, and GVHD was ameliorated
when E coli growth was curtailed by oral polymyxin B,
consistent with the hypothesis that microorganisms can
modulate GVHD [32]. Another murine study conﬁrmed
outgrowth of E coli during GVHD, a ﬁnding interpreted to
represent a shift toward proinﬂammatory bacterial species
[33]. Probiotics appeared to reduce GVHD in experimentalTable 4
Cumulative Incidences of Acute GVHD, Relapse Mortality, and NRM, and Kaplan-Me
Nadir
Posttransplantation
Neutrophil Nadir, Cells/mL
No. of
Patients
Acute GVHD, %
Grade II-IV Grad
750 58 36 3.5
500-749 56 46 5.4
250-499 118 54 9.3
0-249 227 69 11.0models [34], as did oral administration of lactobacillus
rhamnosus, whereas administration of ciproﬂoxacin led to
worse survival, possibly as a result of a disturbedmicrobiome
[35]. These results are consistent with the adverse effect on
GVHD caused by pretreatment of mice with ampicillin and
the reversal of this effect from the introduction of lactobacilli
[12]. Findings in human allogeneic HCT recipients did not
identify special bacterial populations as potential risk factors
for subsequent GVHD, but did show greater microbial
disturbance early after transplantation in patients who
developed GVHD [12]. Sequential high-resolution 16s rRNA
studies of skin and gut microbiomes, especially in patients
with high versus low posttransplantation neutrophil nadirs,
might provide insight into whether microbiome changes
could be implicated in the causal pathway leading to the
development of acute GVHD.
Our second major ﬁnding is that lymphocyte counts
immediately before transplantation had signiﬁcant associa-
tions with the risk of relapse and, consequently, overall
mortality but no association with the risk of acute GVHD,
chronic GVHD, or NRM. Speciﬁcally, patients with higher
lymphocyte counts had signiﬁcantly less risk of relapse or
progression and better OS than those with lower lymphocyte
counts. Because our pretransplantation ﬂow cytometry
examinations of the peripheral blood focused on detecting
malignant cells, we have no detailed information on
lymphocyte and mononuclear subsets in our patients. In the
absence of that knowledge, we hypothesize that lymphocyte
levels might serve as a proxy for the number of host antigen-
presenting cells, with the result that higher counts of these
cells are associated with stronger GVT effects. Even though
our ﬁndings are currently unexplained, they are consistent
with the possibility that GVT effects can be separated from
acute GVHD, and that the 2 entities are initiated by different
mechanisms. Alternatively, it could be argued that pre-
transplantation lymphocyte count reﬂects the intensity of
the preceding chemotherapy adminstered to reduce the
tumor burden. Thus, a low lymphocyte count might be
a surrogate marker for “resilience” of the malignancy to
respond to therapy. To offset this confounder, we adjusted
our analysis for underlying diagnoses.
Four previous studies in HCT recipients treated with
either myeloablative or reduced-intensity conditioning
regimens demonstrated that the risk of relapse was not
reduced by acute GVHD [7,36-38]. In contrast, a recent
large study in patients with leukemias and myelodysplastic
syndromes treated with high-intensity regimens found
signiﬁcant incremental effects of acute GVHD on the risk of
relapse, although this effect was observed only beyond the
ﬁrst 18 months post-HCT [39]. Others have reported GVT
effects associated with acute GVHD in patients with acute
lymphoblastic leukemia and more advanced acute
myelogenous leukemia (AML), but not with AML in ﬁrst
remission [16,40]. Ishiyama et al. [41] reported GVT effects
associated with acute GVHD. A large, retrospective Centerier Estimates of OS in Relation to 4 Ranges of Posttransplantation Neutrophil
Five-Year Relapse
Mortality, %
Five-Year
NRM, %
Five-Year
OS, %
e III-IV
39 3 58
33 9 58
32 15 53
35 25 40
Figure 2. Cumulative incidence rates of relapse mortality (A) and NRM (B) in
relation to 4 neutrophil nadir ranges. The percentages shown in the boxes are
5-year data.
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study [42] analyzed results in recipients of allogeneic HCT
for AML and myelodysplastic syndrome, and found
that acute GVHD after myeloablative conditioning did not
affect relapse, but both chronic GVHD alone and acute
plus chronic GVHD were associated with reduced risk
of relapse. In contrast, all 3 manifestations of GVHD
were associated with highly signiﬁcant reductions in the
risk of relapse in patients who received various reduced-
intensity conditioning regimens. The discordance
between our present results after minimal-intensity
conditioning and some of the previously reported results
after high-intensity conditioning might reﬂect differences
in the diseases treated, with varying susceptibilities to GVT
effects. Previous studies included mainly patients with
acute leukemias and chronic myelogenous leukemia,
whereas more than one-half of our patients had B cell
malignancies, multiple myeloma, or Hodgkin’s lymphoma,
and only 2 patients had chronic myelogenous leukemia.
In conclusion, in our cohort, low posttransplantation
neutrophil counts were predictive of increased risk of acute
GVHD, de novo chronic GHVD, and NRM, whereas high
pretransplantation lymphocyte counts were associated with
a lower risk of relapse and improved survival. These resultssuggest that different mechanisms are involved in the
2 types of localized immunologic graft-versus-host reactions.ACKNOWLEDGMENTS
The authors are grateful to all of the research nurses and
data coordinators who implemented the study protocols; the
many physicians, nurses, physician assistants, nurse practi-
tioners, pharmacists, and support staff who cared for our
patients; and the patients who allowed us to care for them
and participated in our ongoing clinical research. We thank
our administrative staff for their assistance with manuscript
preparation.
Financial disclosure: Research funding was provided by
the National Institutes of Health (grants P01 CA078902, P01
HL036444, P01 CA018029, P30 CA015704, and HL 108307),
the Leukemia & Lymphoma Society (grant 7008-08), and the
Laura Landro Salomon Endowment Fund. The content is
solely the responsibility of the authors and does not neces-
sarily represent the ofﬁcial views of the National Institutes of
Health or any of its subsidiary institutes and centers. The
authors have no primary ﬁnancial relationships with any
company that has a direct ﬁnancial interest in the subject
matter or products discussed in the submittedmanuscript, or
with a company that produces a competing product. The
authors have nothing to disclose.
Authorship statement: Rainer Storb designed research and
wrote themanuscript. Boglarka Gyurkocza assistedwith data
analysis and was principal investigator in one of the clinical
trials. Barry E. Storer performed all statistical analyses. David
G. Maloney served as principal investigator on clinical trials
and contributed to writing the manuscript. Mohamed L.
Sorror served as principal investigator on clinical trials and
contributed to writing the manuscript. Marco Mielcarek
served as principal investigator on clinical trials and
contributed to writing the manuscript. Paul J. Martin super-
vised long-term follow-up of patients and contributed to
writing the manuscript. Brenda M. Sandmaier served as
principal investigator on clinical trials and contributed to
writing the manuscript.REFERENCES
1. Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease [review].
Lancet. 2009;373:1550-1561.
2. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-
host disease by inactivation of host antigen-presenting cells. Science.
1999;285:412-415.
3. Reddy P, Maeda Y, Liu C, et al. A crucial role for antigen-presenting cells
and alloantigen expression in graft-versus-leukemia responses. Nat
Med. 2005;11:1244-1249.
4. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell
transplantation in older patients with hematologic malignancies:
replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
Blood. 2001;97:3390-3400.
5. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unre-
lated donor hematopoietic cell transplantation after nonmyeloablative
conditioning for patients with hematologic malignancies. Blood. 2003;
102:2021-2030.
6. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irra-
diation (TBI) and ﬂudarabine followed by hematopoietic cell trans-
plantation (HCT) from HLA-matched or mismatched unrelated donors
and postgrafting immunosuppression with cyclosporine and myco-
phenolate mofetil (MMF) can induce durable complete chimerism and
sustained remissions in patients with hematological diseases. Blood.
2003;101:1620-1629.
7. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and
graft-versus-tumor effects after hematopoietic cell transplantation.
J Clin Oncol, Published online before print March 11, 2013, doi:10.1200/
JCO.2012.45.0247.
8. Ruutu T, Eriksson B, Remes K, et al. Ursodeoxycholic acid for the
prevention of hepatic complications in allogeneic stem cell trans-
plantation. Blood. 2002;100:1977-1983.
R. Storb et al. / Biol Blood Marrow Transplant 19 (2013) 792e7987989. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allo-
geneic hematopoietic cell transplantation. N Engl J Med. 2010;363:
2091-2101.
10. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9:
244-253. Erratum 9:626.
11. Kosiewicz M, Zirnheld AL, Alard P. Gut microbiota, immunity, and
disease: a complex relationship. Front Microbiol. 2011;2:180.
12. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inﬂammation by
microbiota following allogeneic bone marrow transplantation. J Exp
Med. 2012;209:903-911.
13. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-speciﬁc comorbidity index: a new tool for risk assessment
before allogeneic HCT. Blood. 2005;106:2912-2919.
14. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk among patients
with malignant diseases given allogeneic hematopoietic cell trans-
plantation after nonmyeloablative conditioning. Blood. 2007;110:
2744-2748.
15. Sandmaier BM, Maris M, Storer B, et al. A randomized 3-arm phase II
study to determine the most promising postgrafting immunosup-
pression for prevention of acute graft-versus-host disease (GVHD) after
unrelated donor hematopoietic cell transplantation (HCT) using non-
myeloablative conditioning for patients with hematologic malignan-
cies: a multi-center trial [abstract]. Blood. 2009;114:147.
16. Sullivan KM, Weiden PL, Storb R, et al. Inﬂuence of acute and chronic
graft-versus-host disease on relapse and survival after bone marrow
transplantation from HLA-identical siblings as treatment of acute and
chronic leukemia. Blood. 1989;73:1720-1728.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HLA-
matched sibling donors. Transplantation. 1974;18:295-304.
18. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease
after nonmyeloablative versus conventional hematopoietic stem cell
transplantation. Blood. 2003;102:756-762.
19. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
20. Flowers MED, Inamoto Y, Carpenter PA, et al. Comparative analysis of
risk factors for acute graft-versus-host disease and for chronic graft-
versus-host disease according to National Institutes of Health
consensus criteria. Blood. 2011;117:3214-3219.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
22. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure proba-
bilities in the presence of competing risks: new representations of old
estimators. Stat Med. 1999;18:695-706.
23. Blaser M. Antibiotic overuse: stop the killing of beneﬁcial bacteria.
Nature. 2011;476:393-394.
24. Jernberg C, Lofmark S, Edlund C, et al. Long-term impacts of antibiotic
exposure on the human intestinal microbiota [review]. Microbiology.
2010;156:3216-3223.
25. Dethlefsen L, Relman DA. Incomplete recovery and individualized
responses of the human distal gut microbiota to repeated antibi-
otic perturbation. Proc Natl Acad Sci USA. 2011;108(Suppl 1):
4554-4561.
26. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of
secondary disease in germ-free mouse radiation chimeras. Radiat Res.
1971;45:577-588.27. Heit H, Heit W, Kohne E, et al. Allogeneic bone marrow transplantation
in conventional mice: I. Effect of antibiotic therapy on long-term
survival of allogeneic chimeras. Blut. 1977;35:143-153 (in German).
28. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: inﬂuence
of the microﬂora on graft-versus-host disease after allogeneic bone
marrow transplantation [review]. J Med. 1992;23:161-173.
29. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and
survival in patients with aplastic anemia treated by marrow grafts
from HLA-identical siblings: beneﬁcial effect of a protective environ-
ment. N Engl J Med. 1983;308:302-307.
30. Vossen JM, van den Berg H, Gerritsen EJ, et al. Prevention of infection
and graft-versus-host disease by suppression of intestinal microﬂora in
children treated with allogeneic bone marrow transplantation. Eur
J Clin Microbiol Infect Dis. 1990;9:14-23.
31. Beelen DW, Elmaagacli A, Muller KD, et al. Inﬂuence of intestinal
bacterial decontamination using metronidazole and ciproﬂoxacin or
ciproﬂoxacin alone on the development of acute graft-versus-host
disease after marrow transplantation in patients with hematologic
malignancies: ﬁnal results and long-term follow-up of an open-label
prospective randomized trial. Blood. 1999;93:3267-3275.
32. Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts
intestinal microbial ecology by inhibiting Paneth cell production of
alpha-defensins. Blood. 2012;120:223-231.
33. Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9-mediated
immunopathology and gut microbiota dynamics in a novel murine
model of intestinal graft-versus-host disease. Gut. 2010;59:1079-1087.
34. Gerbitz A, Schultz M, Wilke A, et al. Probiotic effects on experimental
graft-versus-host disease: let them eat yogurt. Blood. 2004;103:
4365-4367.
35. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha
production to lipopolysaccharide stimulation by donor cells predicts
the severity of experimental acute graft-versus-host disease. J Clin
Invest. 1998;102:1882-1891.
36. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects
after allogeneic hematopoietic cell transplantation with non-
myeloablative conditioning. J Clin Oncol. 2005;23:1993-2003.
37. Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is
mainly restricted to NIH-deﬁned chronic graft-versus-host disease
after reduced-intensity conditioning before allogeneic stem cell
transplantation. Leukemia. 2010;24:1852-1858.
38. Cho BS, Lee SE, Song HH, et al. Graft-versus-tumor effect according to
type of graft-versus-host disease deﬁned by National Institutes of
Health consensus criteria and associated outcomes. Biol Blood Marrow
Transplant. 2012;18:1136-1143.
39. Inamoto Y, Flowers MED, Lee SJ, et al. Inﬂuence of immunosuppressive
treatment on risk of recurrent malignancy after allogeneic hemato-
poietic cell transplantation. Blood. 2011;118:456-463.
40. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia
reactions after bone marrow transplantation. Blood. 1990;75:
555-562.
41. Ishiyama K, Takami A, Shiobara S, et al., Kanazawa University Hospital
Haematopoietic Stem Cell Transplantation Group. Graft-versus-
leukemia effect of allogeneic stem cell transplantation: a Japanese
single-center study. Haematologica. 2004;89:887-889.
42. Weisdorf D, Zhang MJ, Arora M, et al. Graft-versus-host disease
induced graft-versus-leukemia effect: greater impact on relapse and
disease-free survival after reduced-intensity conditioning. Biol Blood
Marrow Transplant. 2012;18:1727-1733.
